Medical Condition News

RSS

MagForce Nanotechnologies applies for EU regulatory approval of its Nano-Cancer therapy

MagForce Nanotechnologies AG, the Berlin-based medical nanotechnology company majority owned by Nanostart AG, has submitted its application for the European regulatory approval of its Nano-Cancer® therapy.

2 Dec 2009

Pycnogenol can improve microcirculation, retinal edema and visual acuity, reveals study

According to the National Institute of Health, 40 percent to 45 percent of Americans diagnosed with diabetes already have some stage of diabetic retinopathy.

2 Dec 2009

Early and later treatment options provide similar outcomes in knee injuries, says study

Multiple-ligament knee injuries resulting from traumatic knee dislocations - such as high impact car accidents or certain sports are uncommon, and the optimal timing of surgical repair or reconstruction has not been definitively established.

2 Dec 2009

Human Melanoma Research Team pursuing identification of anti-tumor prognostic markers and drugs

The constant increase in the rate of cutaneous melanoma over recent years and its resistance to anti-tumour pharmaceutical drugs has meant that the study of cutaneous melanoma is one of the greatest scientific challenges in the field of cancer. The Human Melanoma research team at the University of the Basque Country (UPV/EHU) is focusing on this study.

2 Dec 2009

New study indicates pine bark may reduce progressing advanced stages of diabetic retinopathy

According to the National Institute of Health, 40 percent to 45 percent of Americans diagnosed with diabetes already have some stage of diabetic retinopathy. Diabetic retinopathy, damage to the retina caused by leaky blood vessels, is a major cause of blindness in people with diabetes and is one of the most feared diabetic complications. In

2 Dec 2009

Beta 2 adrenergic agonist drugs can increase risk of autism-spectrum disorders in developing fetus

Commonly prescribed beta 2 adrenergic agonist drugs for the treatment of asthma in pregnant women as well as pre-term labor may increase the incidence of autism-spectrum disorders, psychiatric pathology, cognitive problems and poor school performance in their children, according to a new study published in the December 2009 issue of the American Journal of Obstetrics & Gynecology.

2 Dec 2009

nContact Surgical initiates clinical trials of its convergent procedure for paroxysmal AF

nContact Surgical, Inc. ("nContact"), a leader in the investigation of devices for minimally-invasive treatment for heart conditions, today announced the initiation of a feasibility clinical trial designed to evaluate the safety and efficacy of a combined surgical and catheter procedure, the convergent procedure, for the treatment of symptomatic paroxysmal atrial fibrillation (AF). This prospective, feasibility study will enroll patients at study sites across the United States.

2 Dec 2009

Development of novel virus can lead to new therapeutic strategy to combat cancer

Ohio State University cancer researchers have developed a tumor-attacking virus that both kills brain-tumor cells and blocks the growth of new tumor blood vessels.

2 Dec 2009

$Careful diagnosis can help avoid long-term disabilities associated with uncommon fractures$

Careful diagnosis can help avoid long-term disabilities associated with uncommon fractures

Located in areas of the foot that can be hard to visualize with X-rays and other imaging techniques, injuries to the ankle area of the foot are the most frequently misdiagnosed of all foot fractures. Delayed diagnosis can have serious consequences, sometimes leading to permanent disability.

2 Dec 2009

Roche announces results of phase III taspoglutide study in diabetes patients

Ipsen, an innovation-driven global specialty pharmaceutical group, today announced that its partner Roche has disclosed the results of the second and third of eight T-emerge phase III studies in patients with diabetes for taspoglutide, the first human once weekly glucagon-like peptide-1 (GLP-1) analogue originating from Ipsen’s research and developed by Roche.

2 Dec 2009

Bioactive sponge to eliminate normally fatal tumors

InCytu Incorporated, a therapeutic device engineering company, announced the details of its Cellarium™ Cancer Vaccine program. Cellarium™ is a small bioactive sponge which regulates dendritic cells and T-cells to eliminate normally fatal tumors in a preclinical model of late stage melanoma. The details of such a promising new vaccine were published for the first time in Science’s Translational Medicine Journal.

2 Dec 2009

Harvest Technologies' BMAC System exhibits potential as an effective treatment for CLI

Harvest Technologies Corp. announced today results from the company sponsored 60-patient clinical trial conducted at Sri Ramachandra Medical Center in Chennai, India using the company's BMAC System to treat patients with non-reconstructable Critical Limb Ischemia (CLI). Sri Ramachandra Medical Center is a Harvard Medical international-associated institution based in Chennai, India and one of the largest private healthcare facilities in South Asia.

2 Dec 2009

ImThera Medical implants its aura6000 neurostimulation device in two OSA patients

ImThera Medical, Inc. today announced that two patients have been surgically implanted with ImThera’s aura6000™ neurostimulation device for treating tongue-based Obstructive Sleep Apnea (OSA). Patients are being enrolled in ImThera’s pilot clinical investigation in Belgium with the first results expected to be published in the first half of 2010.

2 Dec 2009

Cancer Prevention Research Conference highlights new research on cancer

The American Association for Cancer Research Frontiers in Cancer Prevention Research Conference will focus on the latest biological, medical and social research behind cancer prevention.

2 Dec 2009

ASH Annual Meeting to showcase latest research and treatments for blood disorders

The American Society of Hematology (ASH), the world's largest professional association of blood specialists, expects more than 20,000 attendees at the 51st ASH Annual Meeting from December 5-8, 2009, at the Ernest N. Morial Convention Center in New Orleans, LA. The meeting will showcase the latest research and treatments for blood disorders.

2 Dec 2009

New approach to identify molecules that prevent immune cells from attacking body

A study led by a Scripps Research Institute scientist describes a new, highly pragmatic approach to the identification of molecules that prevent a specific type of immune cells from attacking their host. The findings add a powerful new tool to the ongoing search for potential treatments for autoimmune diseases, such as multiple sclerosis (MS), as well as blood cancers, such as myeloid leukemia.

2 Dec 2009

Researchers develop new application for improved detection of breast cancer cells

Single-walled nanotubes—cylinders of carbon about a nanometer in diameter—have been highly touted for potential applications such as ultrastrong fibers, electrical wires in molecular devices, or hydrogen storage components for fuel cells. Thanks to a new development by researchers at the National Institute of Standards and Technology (NIST) and five partners, you can add one more application to the list: detection and destruction of an aggressive form of breast cancer.

2 Dec 2009

Boehringer Ingelheim to announce positive results from its RE-COVER study

Boehringer Ingelheim will announce positive results from the landmark RE-COVER™ study at the 51st Annual Meeting of the American Society of Hematology on 6 December 2009. The RE-COVER™ study assessed dabigatran etexilate in a head-to-head comparison with the current standard in care, warfarin, for the treatment of acute venous thromboembolism (VTE), enabling healthcare professionals to make direct comparisons and care based value judgements.

2 Dec 2009

J&JPRD submits an NDA for tapentadol ER tablets

Johnson & Johnson Pharmaceutical Research & Development, L.L.C. announced today that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for tapentadol extended release (ER) tablets, an investigational oral analgesic for the management of moderate to severe chronic pain in patients 18 years of age or older.

2 Dec 2009

New preventive screening packages for heart disease

HealthYes!®, a leading mobile medical screening provider, is offering several new preventive screenings directly focused on heart disease. The new tests include: a six-lead electrocardiogram (EKG), cholesterol finger-stick, and 10-year Framingham Cardiac Risk Score as well as diabetes and liver function testing.

2 Dec 2009

Medical Condition News

MagForce Nanotechnologies applies for EU regulatory approval of its Nano-Cancer therapy

Pycnogenol can improve microcirculation, retinal edema and visual acuity, reveals study

Early and later treatment options provide similar outcomes in knee injuries, says study

Human Melanoma Research Team pursuing identification of anti-tumor prognostic markers and drugs

New study indicates pine bark may reduce progressing advanced stages of diabetic retinopathy

Beta 2 adrenergic agonist drugs can increase risk of autism-spectrum disorders in developing fetus

nContact Surgical initiates clinical trials of its convergent procedure for paroxysmal AF

Development of novel virus can lead to new therapeutic strategy to combat cancer

Careful diagnosis can help avoid long-term disabilities associated with uncommon fractures

Roche announces results of phase III taspoglutide study in diabetes patients

Bioactive sponge to eliminate normally fatal tumors

Harvest Technologies' BMAC System exhibits potential as an effective treatment for CLI

ImThera Medical implants its aura6000 neurostimulation device in two OSA patients

Cancer Prevention Research Conference highlights new research on cancer

ASH Annual Meeting to showcase latest research and treatments for blood disorders

New approach to identify molecules that prevent immune cells from attacking body

Researchers develop new application for improved detection of breast cancer cells

Boehringer Ingelheim to announce positive results from its RE-COVER study

J&JPRD submits an NDA for tapentadol ER tablets

New preventive screening packages for heart disease

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Latest News